Stay updated on Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page
- Check5 days agoChange DetectedAdded a site-wide notice about potential delays due to government funding and the NIH Clinical Center status. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check12 days agoChange DetectedThe additions and deletions are minor metadata and UI updates, including showing the glossary, new 'Last Update' fields, and a revision bump from v3.3.4 to v3.4.0, with some metadata items removed or reformatted. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check19 days agoChange DetectedAdded Principal Investigator: Timothy Voorhees, MD, and protocol implementation contact details (CTO.Implementation@osumc.edu; 614-293-3717) for Ohio State University Comprehensive Cancer Center. Expanded the Locations/Recruiting sections to six sites with explicit Columbus, Ohio addresses and updated recruitment status.SummaryDifference1%

- Check26 days agoChange DetectedRevision: v3.3.4 updates the page from v3.3.3; no study content or eligibility details appear affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page now includes a dedicated Locations section listing study sites in Illinois, Indiana, Iowa, Minnesota, and Wisconsin. The separate Illinois Locations entry and related footer label have been removed as part of this update.SummaryDifference0.6%

- Check75 days agoChange DetectedThe page's revision label was updated from v3.2.0 to v3.3.2, a minor administrative change that does not affect study content or details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.